IL28B

A new marker for SVR prediction in HCV-infected patients

Enrico Galmozzi, Alessio Aghemo

Research output: Contribution to journalArticle

Abstract

The treatment currently recommended for chronic infection with the hepatitis C virus (HCV) involves a course of peg-interferon alpha combined with ribavirin of variable duration. In the face of the elevated costs of the two drugs and the potentially serious adverse events related to combination therapy the identification of baseline predictors of treatment response that may identify patients with little or no chance of achieving a sustained virological response is of paramount importance. In 2009 a genome-wide association study on the IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess optimal pegyLated interferon therapy) study population and a small group of patients from another cohort identified rs12979860 a single nucleotide polymorphism (SNP) located on chromosome 19 near the IL28B gene encoding for interferon lambda-3 was found to be strongly associated with sustained virological response (SVR). The independent external validation of this pivotal study coupled with the demonstration that the IL28B SNP affects treatment outcome in other HCV genotypes has led to the incorporation of this test into the current pretreatment algorithm of HCV-infected patients.

Original languageEnglish
Pages (from-to)29-34
Number of pages6
JournalHot Topics in Viral Hepatitis
Issue number22
Publication statusPublished - 2011

Fingerprint

Hepacivirus
Interferons
Single Nucleotide Polymorphism
Chromosomes, Human, Pair 19
Drug Costs
Ribavirin
Validation Studies
Genome-Wide Association Study
Therapeutics
Interferon-alpha
Genotype
Infection
Population
Genes

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

IL28B : A new marker for SVR prediction in HCV-infected patients. / Galmozzi, Enrico; Aghemo, Alessio.

In: Hot Topics in Viral Hepatitis, No. 22, 2011, p. 29-34.

Research output: Contribution to journalArticle

@article{f4bec3ee39194becb19d3df0b549bb01,
title = "IL28B: A new marker for SVR prediction in HCV-infected patients",
abstract = "The treatment currently recommended for chronic infection with the hepatitis C virus (HCV) involves a course of peg-interferon alpha combined with ribavirin of variable duration. In the face of the elevated costs of the two drugs and the potentially serious adverse events related to combination therapy the identification of baseline predictors of treatment response that may identify patients with little or no chance of achieving a sustained virological response is of paramount importance. In 2009 a genome-wide association study on the IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess optimal pegyLated interferon therapy) study population and a small group of patients from another cohort identified rs12979860 a single nucleotide polymorphism (SNP) located on chromosome 19 near the IL28B gene encoding for interferon lambda-3 was found to be strongly associated with sustained virological response (SVR). The independent external validation of this pivotal study coupled with the demonstration that the IL28B SNP affects treatment outcome in other HCV genotypes has led to the incorporation of this test into the current pretreatment algorithm of HCV-infected patients.",
author = "Enrico Galmozzi and Alessio Aghemo",
year = "2011",
language = "English",
pages = "29--34",
journal = "Hot Topics in Viral Hepatitis",
issn = "1973-9648",
publisher = "FBCommunication srl",
number = "22",

}

TY - JOUR

T1 - IL28B

T2 - A new marker for SVR prediction in HCV-infected patients

AU - Galmozzi, Enrico

AU - Aghemo, Alessio

PY - 2011

Y1 - 2011

N2 - The treatment currently recommended for chronic infection with the hepatitis C virus (HCV) involves a course of peg-interferon alpha combined with ribavirin of variable duration. In the face of the elevated costs of the two drugs and the potentially serious adverse events related to combination therapy the identification of baseline predictors of treatment response that may identify patients with little or no chance of achieving a sustained virological response is of paramount importance. In 2009 a genome-wide association study on the IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess optimal pegyLated interferon therapy) study population and a small group of patients from another cohort identified rs12979860 a single nucleotide polymorphism (SNP) located on chromosome 19 near the IL28B gene encoding for interferon lambda-3 was found to be strongly associated with sustained virological response (SVR). The independent external validation of this pivotal study coupled with the demonstration that the IL28B SNP affects treatment outcome in other HCV genotypes has led to the incorporation of this test into the current pretreatment algorithm of HCV-infected patients.

AB - The treatment currently recommended for chronic infection with the hepatitis C virus (HCV) involves a course of peg-interferon alpha combined with ribavirin of variable duration. In the face of the elevated costs of the two drugs and the potentially serious adverse events related to combination therapy the identification of baseline predictors of treatment response that may identify patients with little or no chance of achieving a sustained virological response is of paramount importance. In 2009 a genome-wide association study on the IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess optimal pegyLated interferon therapy) study population and a small group of patients from another cohort identified rs12979860 a single nucleotide polymorphism (SNP) located on chromosome 19 near the IL28B gene encoding for interferon lambda-3 was found to be strongly associated with sustained virological response (SVR). The independent external validation of this pivotal study coupled with the demonstration that the IL28B SNP affects treatment outcome in other HCV genotypes has led to the incorporation of this test into the current pretreatment algorithm of HCV-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=84859091148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859091148&partnerID=8YFLogxK

M3 - Article

SP - 29

EP - 34

JO - Hot Topics in Viral Hepatitis

JF - Hot Topics in Viral Hepatitis

SN - 1973-9648

IS - 22

ER -